GMP peptide manufacturing, pharmacology/toxicology, and scaled radionuclide production and validation for PB-212 receptor targeted alpha-particle therapy clinical trials for metastatic melanoma

Ended Project Grant Awarded Last action

Award ID
R44CA254613
Recipient
Awarding agency
Obligated
$1,999,766

Award facts

Assistance listing
93.395 Cancer Treatment Research
Completion date
Place of performance
Iowa, USA

Award details come from USAspending.gov.

Transactions

Action Obligated Date
Amendment $0
Amendment $999,883
Amendment $0
Amendment $0
Original award $999,883

Quick answers

Who received award R44CA254613?

R44CA254613 was awarded to Viewpoint Molecular Targeting, Inc. by National Cancer Institute (National Institutes of Health) on September 7, 2020.

How much is award R44CA254613 worth?

$1,999,766 has been obligated on R44CA254613.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award